Table 4.
Definitive Radiochemotherapy (DRCT) for elderly patients (EP) vs. younger patients (YP) with oesophageal cancer.
| Author, Year [Reference] |
EP Definition (Years) |
No of EP (%)% of SCC | DRCT Details | cCR% | Hematologic Toxicity, % (>Grade II) | Pulmonary Toxicity, % (>Grade II) | Esophagitis% (>Grade II) |
Progression-Free Survival | Survival Overall |
|---|---|---|---|---|---|---|---|---|---|
| EP/YP | EP/YP | EP/YP | EP/YP | EP/YP | EP/YP | ||||
| Jingu, 2020 [77] | 80 | 358 (15.3) 96.1 |
- | - | - | - | - | - | 13/52 * 5-year, (%) |
| Vöncken, 2017 [27] | 70 | 76 (30) 33 |
Carbo-Taxol + 50 Gy | 48/31 | - | - | - | 20.5/7.4 * | 23.6/13.1 * |
| Münch, 2017 [19] | 75 | 32 (45) 81 |
5FU/Cisplatin + 7–60 Gy | - | 13/29 | - | - | 10/9 median, (mo) | 16/20 median, (mo) |
| Xu, 2017 [72] |
80 | 56 (20) 29 |
5FU/Taxane + 45–50.4 Gy | 78/56 * | 4/12 | 11/0 * | 16/14 | 58/56 5-year (%) |
28/23 median, (mo) |
| Davies, 2010 [14] | 70 | 106 (45) 51 |
5FU/Cisplatin + 50 Gy | 22/19 | - | 7/7 | - | 22/21 median, (mo) |
|
| Takagawa, 2008 [25] | 75 | 19 (9) 84 |
5FU + 60 Gy | 66/67 | - | - | - | - | 15/10 median, (mo) |
| Takeuchi, 2007 [73] | 70 | 33 (19) 100 |
5FU/Cisplatin + 60 Gy | 64/63 | 70/50 * | - | 3/9 | - | 15/35 * median, (mo) |
| Tanisada, 2000 [74] | 75 | 123 (22) NA |
- | - | - | - | - | - | 9/11 5-year, (%) |
DCRT = Definitive Chemoradiation, EP = Elderly patients, YP = Younger Patients, SCC = Squamous Cell Carcinoma, Ccr = clinical Complete Response, NA = Not Available. Significant p-values < 0.05 are indicated with an asterisk *. Italics indicate the percentage of SCC tumors in all included studies.